DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostics Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
The companion diagnostics (CDx) market is projected to grow at a CAGR of 13.14% to reach US$8.974 billion by 2024, from US$4.278 billion in 2018.
A companion diagnostic is a medical device, often an in vitro device (IVD), which provides information that is essential for the safe and effective use of a corresponding drug or biological product (source: FDA). The growing prevalence of chronic disorders and the improving regulatory framework for supporting drug-diagnostic co-development models are driving the growth of the global companion diagnostics (CDx) market. The advent of precision medicine and precision medicine diagnostics improving the quality of a patient's life will further fuel the growth of the global companion diagnostics market in the forecast period and beyond.
The Companion Diagnostics Market - Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by technology and indication, and geography.
Major players in the companion diagnostics market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the companion diagnostics market.
Key Topics Covered:
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY
5.1. Polymerase Chain Reaction (PCR)
5.2. Immunohistochemistry (IHC)
5.3. In-situ Hybridization (ISH)
5.4. Next-Generation Sequencing (NGS)
6. COMPANION DIAGNOSTICS MARKET BY INDICATION
6.1. Lung Cancer
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Other Oncology and non-oncology diseases
7. COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY
7.1. North America
7.1.1. United States
7.2. South America
7.3.1. United Kingdom
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.5. Asia Pacific
7.5.4. South Korea
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Abbott Laboratories
9.2. Agilent Technologies, Inc.
9.3. ARUP Laboratories
9.4. F. Hoffmann-La Roche Ltd
9.5. Illumina, Inc.
9.7. Myriad Genetics, Inc.
9.9. Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/wo4a2r